Hydrogenology
Hydrogenology editorial study record

A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease

Tao G et al. · J Cell Mol Med. 2022;26(14):4113–4123.

HumanInhaled H₂Published 2022
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized placebo-controlled parallel trial with additional animal and cell experiments

Research topic

Liver health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adults aged 30–70 with non-alcoholic fatty liver disease

Sample

62 randomized; 43 completed: H₂–O₂ n=21 and placebo n=22

Duration

13 weeks

Intervention

Mixed gas by inhalation at 3,000 mL/min for 1 hour daily

Hydrogen form

Brown’s gas / oxyhydrogen — H₂ and O₂ co-delivered, not H₂ alone.

H₂ specification

66% H₂ + 33% O₂ by volume as reported; the remaining 1% is not specified.

H₂ flow

1,980 mL/min H₂, calculated as 3,000 mL/min total mixed-gas flow × 66% H₂.

O₂ delivered with H₂

990 mL/min O₂, calculated as 3,000 mL/min × 33% O₂.

Comparator

Normal air containing 78.1% N₂ and 20.9% O₂ at 3,000 mL/min

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Liver enzymes, lipids, ultrasound and CT liver-fat measures, oxidative and inflammatory markers

Reported result

Several lipid and liver-enzyme measures improved. In moderate-to-severe subgroups, imaging changes favored H₂–O₂; the complete sample was small and subgroup analyses were emphasized.

Results-extraction completeness

Human intervention, gas composition, flow, outcome tables, funding and conflicts checked in the open-access full text; independent appraisal remains incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Nineteen of 62 randomized participants did not complete the study, the analyzed sample was 43, and imaging claims emphasize small severity subgroups. Asclepius Meditec provided generators; authors declared no conflicts and public grants funded the work.

Applies directly to

Adults with NAFLD meeting the study criteria; the animal and cell experiments do not add independent human participants.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 35734974 · DOI: 10.1111/jcmm.17456

Publisher access

Open-access full text is available through PMC and the publisher.

Extraction basis

Open-access PMC and publisher full texts plus PubMed bibliographic record.

Record revision

2026-08-10